Mind Medicine

MNMD62

High Growth

$7.76arrow_drop_down7.62%-$0.64

High Growth

MNMD62

$7.76

arrow_drop_down7.62%-$0.64

High Growth

Performance History

Key Stats
Open	$9.00
Prev. Close	$8.39
EPS	-1.71
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	7.73	9.77
52 Week Range	2.41	12.22

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.71

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Mind Medicine (MNMD)

Mind Medicine (MNMD) is a pharmaceutical company that focuses on the development of psychedelic medicines to treat mental health disorders. The company's primary aim is to create innovative therapies for patients who have not responded well to traditional treatments. MNMD stock has shown significant growth in recent years, attracting the attention of investors and analysts alike. With a market cap of [INSERT MARKET CAP], MNMD has become a key player in the emerging field of psychedelic medicine.

MNMD stock price history shows a positive trend, with consistent growth over the past year. This increase can be attributed to the growing acceptance of psychedelic therapies and the potential they hold for treating various mental health conditions. The stock has also been positively influenced by news of successful clinical trials and FDA approvals for Mind Medicine's experimental treatments.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Robert Barrow
Headquarters: New York
Employees: 48
Exchange: NASDAQ

Keep an eye on Mind Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Mind Medicine 's (MNMD) price per share?

The current price per share for Mind Medicine (MNMD) is $7.76. The stock has seen a price change of -$0.64 recently, indicating a -7.63% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Mind Medicine (MNMD)?

For Mind Medicine (MNMD), the 52-week high is $12.22, which is 57.47% from the current price. The 52-week low is $2.41, the current price is 221.99% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Mind Medicine (MNMD) a growth stock?

Mind Medicine (MNMD) has shown an average price growth of -6.65% over the past three years. It has received a score of 83 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Mind Medicine as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Mind Medicine (MNMD) stock price performance year to date (YTD)?

As of the latest data, Mind Medicine (MNMD) has a year-to-date price change of 114.36%. Over the past month, the stock has experienced a price change of 19.57%. Over the last three months, the change has been 22.01%. Over the past six months, the figure is -10.29%.

help

Is Mind Medicine (MNMD) a profitable company?

Mind Medicine (MNMD) has a net income of -$95.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$93.87M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Mind Medicine (MNMD)?

Mind Medicine (MNMD) has a market capitalization of $569.05M. The average daily trading volume is 8.66, indicating the stock's liquidity and investor engagement.